Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice.
Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice.
复制标题
DOI：
10.1177/1758835918768238
复制
发表时间：
2018
影响因子：
4.9
通讯作者：
Kontakiotis T
中科院分区：
文献类型：
--
作者：
Boutsikou E;Domvri K;Hardavella G;Tsiouda D;Zarogoulidis K;Kontakiotis T
新型抗程序性细胞死亡蛋白-1（PD-1）抑制剂在非小细胞肺癌（NSCLC）中的出现彻底改变了这种疾病的治疗前景。尽管晚期NSCLC一线和二线治疗的总生存期（OS）有所改善，但获益并不普遍。在全球审查医疗保健成本和与免疫治疗相关的潜在毒性的环境下，适当的患者选择至关重要。本研究的目的是评价外周血中潜在的预后和预测生物标志物干扰素-γ（IFN-γ）、肿瘤坏死因子-α（TNF-α）和一组白细胞介素（IL），并评估NSCLC患者对抗PD-1抑制的应答、无进展生存期和OS的任何相关性。我们前瞻性研究了26例接受免疫治疗（pembrolizumab或nivolumab）的NSCLC患者。在诊断时和开始抗PD-1抑制后3个月，通过流式细胞术分析IFN-γ、TNF-α、IL-1β、IL-2、IL-4、IL-5、IL-6、IL-8、IL-10和IL-12。在诊断时和治疗开始后3个月，细胞因子值（IFN-γ、TNF-α、IL-1β、IL-2、IL-4、IL-6和IL-8）升高与免疫治疗反应改善和OS延长显著相关。细胞因子水平与程序性细胞死亡配体-1（PD-L1）表达之间无相关性。IFN-γ、TNF-α、IL-1β、IL-2、IL-4、IL-5、IL-6、IL-8、IL-10和IL-12水平升高导致对NSCLC抗PD-1抑制剂的反应更好和生存期更长，这可能在选择将从抗PD-1抑制剂中获益的患者方面发挥重要作用。
The emergence of novel antiprogrammed cell death protein-1 (PD-1) inhibitors in non-small cell lung cancers (NSCLC) has revolutionized the therapeutic landscape of this disease. Although overall survival (OS) has improved in the first- and second-line therapy settings for advanced NSCLC, the benefit is not universal. In a climate of global scrutiny for healthcare costs and potential for toxicities related to immunotherapy, appropriate patient selection is crucial. The aim of this study was to evaluate potential prognostic and predictive biomarkers interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and a panel of interleukins (ILs) in the peripheral blood, and assess any correlation with response to anti-PD-1 inhibition, progression-free survival and OS in NSCLC patients. We prospectively studied 26 NSCLC patients that received immunotherapy (either pembrolizumab or nivolumab). IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and IL-12 were analyzed by flow cytometry at the time of diagnosis and at 3 months after initiation of anti-PD-1 inhibition. Increased cytokine values (IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-6 and IL-8) at the time of diagnosis and at 3 months after initiation of treatment were significantly correlated with improved response to immunotherapy and prolonged OS. There was no correlation between cytokine levels and programmed cell death ligand-1 (PD-L1) expression. Increased IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and IL-12 levels resulted in better response to NSCLC anti-PD-1 inhibition and longer survival, and this could potentially play an important role in selecting patients that would benefit from anti-PD-1 inhibitors.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
DOI：
10.1634/theoncologist.2015-0507
发表时间：
2016-05
期刊：
The oncologist
影响因子：
--
作者：
Kazandjian D;Suzman DL;Blumenthal G;Mushti S;He K;Libeg M;Keegan P;Pazdur R
通讯作者：
Pazdur R
影响因子：
64.8
作者：
Shankaran, V;Ikeda, H;Schreiber, RD
通讯作者：
Schreiber, RD
影响因子：
4.6
作者：
Zhang M;Li G;Wang Y;Wang Y;Zhao S;Haihong P;Zhao H;Wang Y
通讯作者：
Wang Y
DOI：
10.1016/s0140-6736(16)32517-x
发表时间：
2017-01-21
期刊：
Lancet (London, England)
影响因子：
--
作者：
Rittmeyer A;Barlesi F;Waterkamp D;Park K;Ciardiello F;von Pawel J;Gadgeel SM;Hida T;Kowalski DM;Dols MC;Cortinovis DL;Leach J;Polikoff J;Barrios C;Kabbinavar F;Frontera OA;De Marinis F;Turna H;Lee JS;Ballinger M;Kowanetz M;He P;Chen DS;Sandler A;Gandara DR;OAK Study Group
通讯作者：
OAK Study Group